4.6 Article

Large-Scale Gene-Centric Analysis Identifies Novel Variants for Coronary Artery Disease

Journal

PLOS GENETICS
Volume 7, Issue 9, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pgen.1002260

Keywords

-

Funding

  1. British Heart Foundation (BHF)
  2. UK Medical Research Council
  3. Leicester NIHR Biomedical Research Unit in Cardiovascular Disease
  4. AMC (The Netherlands)
  5. LURIC (Germany)
  6. University of Cambridge (UK)
  7. Wellcome Trust Sanger Institute (UK)
  8. Bloodomics [LSHM-CT-2004-503485]
  9. British Heart Foundation [RG/09/12/28096]
  10. National Institute for Health Research [RP-PG-0310-1002]
  11. Netherlands Heart Foundation [2001D019, 2003T302, 2007B202]
  12. Leducq Foundation [05-CVD]
  13. Center for Translational Molecular Medicine (CTMM COHFAR)
  14. Interuniversity Cardiology Institute of The Netherlands
  15. LURIC [LSHM-CT-2004-503485]
  16. European Union [201668, LSHM-CT-2006-037593]
  17. National Heart, Lung, and Blood Institute
  18. Helmholtz Zentrum Munchen
  19. German Research Center for Environmental Health
  20. Neuherberg, Germany
  21. German Federal Ministry of Education and Research (BMBF)
  22. German National Genome Research Network [01GS0834]
  23. University of Ulm
  24. Munich Center of Health Sciences (MC Health)
  25. Penn Cardiovascular Institute
  26. GlaxoSmithKline
  27. British Heart Foundation
  28. European Community [LSHM-CT-2007-037273]
  29. AstraZeneca
  30. Wellcome Trust
  31. United Kingdom Medical Research Council
  32. Swedish Heart-Lung Foundation
  33. Swedish Medical Research Council
  34. Knut and Alice Wallenberg Foundation
  35. Torsten and Ragnar Soderberg Foundation
  36. Karolinska Institutet and Stockholm County Council
  37. Foundation for Strategic Research
  38. Stockholm County Council [560283]
  39. University of Cambridge and in Pakistan
  40. EU Framework 6-funded Bloodomics Integrated Project [LSHM-CT-2004-503485]
  41. Yousef Jameel Foundation
  42. European Commission (SANCO)
  43. Dutch Ministry of Health
  44. Dutch Cancer Society
  45. ZonMW
  46. Netherlands Organisation for Health Research and Development
  47. World Cancer Research Fund (WCRF)
  48. NL Agency [IGE 05012]
  49. Organization for Scientific Research (NWO)
  50. Netherlands Heart Foundation (NHS) [2001.064]
  51. TI Pharma [T6-101]
  52. Novo Nordisk
  53. Top Institute Pharma
  54. Dutch Medicines Evaluation Board
  55. MRC [G0700931, G0701863, MC_U105260792, MC_U137686857, G0801056, G0601966] Funding Source: UKRI
  56. British Heart Foundation [RG/08/014/24067] Funding Source: researchfish
  57. Medical Research Council [G0700931, G0801056, MC_U106179471, G0801056B, G0601966, G0701863, G0401527, MC_U105260792, MC_U137686857, G1000143] Funding Source: researchfish
  58. National Institute for Health Research [CL-2010-11-001, RP-PG-0310-1002] Funding Source: researchfish

Ask authors/readers for more resources

Coronary artery disease (CAD) has a significant genetic contribution that is incompletely characterized. To complement genome-wide association (GWA) studies, we conducted a large and systematic candidate gene study of CAD susceptibility, including analysis of many uncommon and functional variants. We examined 49,094 genetic variants in similar to 2,100 genes of cardiovascular relevance, using a customised gene array in 15,596 CAD cases and 34,992 controls (11,202 cases and 30,733 controls of European descent; 4,394 cases and 4,259 controls of South Asian origin). We attempted to replicate putative novel associations in an additional 17,121 CAD cases and 40,473 controls. Potential mechanisms through which the novel variants could affect CAD risk were explored through association tests with vascular risk factors and gene expression. We confirmed associations of several previously known CAD susceptibility loci (eg, 9p21.3:p<10(-33); LPA:p<10(-19); 1p13.3:p<10(-17)) as well as three recently discovered loci (COL4A1/COL4A2, ZC3HC1, CYP17A1:p<5x10(-7)). However, we found essentially null results for most previously suggested CAD candidate genes. In our replication study of 24 promising common variants, we identified novel associations of variants in or near LIPA, IL5, TRIB1, and ABCG5/ABCG8, with per-allele odds ratios for CAD risk with each of the novel variants ranging from 1.06-1.09. Associations with variants at LIPA, TRIB1, and ABCG5/ABCG8 were supported by gene expression data or effects on lipid levels. Apart from the previously reported variants in LPA, none of the other similar to 4,500 low frequency and functional variants showed a strong effect. Associations in South Asians did not differ appreciably from those in Europeans, except for 9p21.3 (per-allele odds ratio: 1.14 versus 1.27 respectively; P for heterogeneity = 0.003). This large-scale gene-centric analysis has identified several novel genes for CAD that relate to diverse biochemical and cellular functions and clarified the literature with regard to many previously suggested genes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available